Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
暂无分享,去创建一个
Glay Chinea | Osmany Guirola | Vivian Huerta | G. Chinea | Osmany Guirola | V. Huerta | E. Montero | Y. Puchades | Ruby Alonso | Joel de Leon | Patricia Piedra | Yaquelin Puchades | Enrique Montero | Patricia Piedra | J. de León | Ruby Alonso | J. de León
[1] L. Beretta,et al. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. , 2002, International immunology.
[2] G Vriend,et al. WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.
[3] B. Haynes,et al. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells , 1995, The Journal of experimental medicine.
[4] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Lalouel,et al. Lipoprotein Lipase Binds to Low Density Lipoprotein Receptors and Induces Receptor-mediated Catabolism of Very Low Density Lipoproteins in Vitro* , 1996, The Journal of Biological Chemistry.
[6] J. A. Titus,et al. Fragmentation of immunoglobulin G. , 2001, Current protocols in immunology.
[7] T. A. Hall,et al. BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .
[8] J. Bajorath,et al. Characterization of mouse ALCAM (CD166): the CD6‐binding domain is conserved in different homologs and mediates cross‐species binding , 1997, European journal of immunology.
[9] E. Reinherz,et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[10] C. Morimoto,et al. Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation. , 1989, Molecular immunology.
[11] E. Montero,et al. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. , 1999, Autoimmunity.
[12] F. Sánchez‐Madrid,et al. Relevance of CD6-Mediated Interactions in T Cell Activation and Proliferation1 , 2004, The Journal of Immunology.
[13] R. Kinne,et al. Evidence for the expression of a second CD6 ligand by synovial fibroblasts. , 2000, Arthritis and rheumatism.
[14] M. Saifullah,et al. Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues1 , 2004, The Journal of Immunology.
[15] R. Timpl,et al. Crystal structure of a scavenger receptor cysteine-rich domain sheds light on an ancient superfamily , 1999, Nature Structural Biology.
[16] C. Jones,et al. Higher rate of evolution of X chromosome alpha‐repeat DNA in human than in the great apes. , 1992, The EMBO journal.
[17] E. Coligan. Current protocols in immunology , 1991 .
[18] J. Bajorath,et al. Identification of residues in CD6 which are critical for ligand binding. , 1997, Biochemistry.
[19] F. Felici,et al. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. , 1991, Journal of molecular biology.
[20] B. Modrell,et al. The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site (*) , 1995, The Journal of Biological Chemistry.
[21] U. Holmskov,et al. The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. , 2004, Critical reviews in immunology.
[22] J. Coloma,et al. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. , 2000, Hybridoma.
[23] P. Linsley,et al. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins , 1991, The Journal of experimental medicine.
[24] J. Hansen,et al. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. , 1981, Journal of immunology.
[25] Danica Stanimirovic,et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system , 2008, Nature Immunology.
[26] A Sali,et al. Comparative protein modeling by satisfaction of spatial restraints. , 1996, Molecular medicine today.
[27] S. Chow,et al. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. , 1994, Cellular immunology.
[28] F. Sánchez‐Madrid,et al. The Accessory Molecules CD5 and CD6 Associate on the Membrane of Lymphoid T Cells* , 2003, The Journal of Biological Chemistry.
[29] J. Bajorath,et al. The Amino-terminal Immunoglobulin-like Domain of Activated Leukocyte Cell Adhesion Molecule Binds Specifically to the Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 with a 1:1 Stoichiometry* , 1996, The Journal of Biological Chemistry.
[30] J. Yélamos,et al. CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock , 2007, Proceedings of the National Academy of Sciences.
[31] R. Dernick,et al. Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels , 1988, Electrophoresis.
[32] A. Barclay,et al. Frontline: Optimal T cell activation requires the engagement of CD6 and CD166 , 2004, European journal of immunology.
[33] J. Swack,et al. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. , 1989, Journal of immunology.
[34] J. Mier,et al. Biosynthesis and post-translational modification of CD6, a T cell signal-transducing molecule. , 1991, The Journal of biological chemistry.
[35] E. Reinherz,et al. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. , 1983, Transplantation.
[36] C. Morimoto,et al. Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. , 1993, International immunology.
[37] R. Pérez,et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. , 2003, Hybridoma and hybridomics.
[38] M. Wilchek,et al. The use of the avidin-biotin complex as a tool in molecular biology. , 2006, Methods of biochemical analysis.
[39] G. P. Smith,et al. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.
[40] E. Reinherz,et al. Immunologic responses of progressive multiple sclerosis patients treated with an anti‐T‐cell monoclonal antibody, anti‐T12 , 1986, Neurology.
[41] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.